Schrodinger, Inc.
SDGR evidence brief
What we can confirm
- BioSniper Score:
- 5.1 / 10
- Market Cap:
- $1.42B
- Lead Asset:
- sgr-1505 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for SDGR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SDGR
Schrödinger, Inc. (SDGR) is a computational drug discovery company that develops a physics-based software platform and advances its own proprietary pipeline of preclinical and clinical drug programs.
Key risk: Early-stage pipeline
BioSniper Score
Based on 4 of 6 signals
Market Cap
$1.42B
Cash Runway
—
Lead Asset
sgr-1505 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates for Schrodinger, Inc..
Schrödinger, Inc. (SDGR) is a computational drug discovery company that develops a physics-based software platform and advances its own proprietary pipeline of preclinical and clinical drug programs.
- Generated 2025 total revenue of $255.9 million, up 23.3% over 2024 [sec · filed 2026-04-28]
- Cash & equivalents of $287.9M as of 2026-06-30 [sec]
- Phase 1 clinical trial ongoing for SGR-1505 (MALT1 inhibitor) in relapsed/refractory B-cell malignancies [sec_mda · as of 2026-05-05]
- Phase 1 clinical trial ongoing for SGR-3515 (Wee1/Myt1 co-inhibitor) in advanced solid tumors [sec · filed 2026-04-28]
- Launched a predictive toxicology solution commercially, funded in part by a $24.5M grant from the Gates Foundation [sec_mda · as of 2026-08-05]
What works
- Strong revenue growth: 2025 total revenue increased 23.3% year-over-year to $255.9M, with software revenue up 10.6% to $199.5M [sec · filed 2026-04-28]
- Substantial cash position: $287.9M in cash & equivalents as of 2026-06-30 provides runway for R&D and operations [sec]
- Expanded collaborations with major pharma partners including Ajax Therapeutics, Eli Lilly, and Otsuka Pharmaceutical [sec · filed 2026-04-28]
- Predictive toxicology initiative funded by a $24.5M Gates Foundation grant and now commercially launched [sec_mda · as of 2026-08-05]
What to weigh
- Both clinical programs (SGR-1505 and SGR-3515) are still in Phase 1 dose-escalation, with no later-stage data yet [sec_mda · as of 2026-05-05]
- Company plans to seek strategic partnerships for SGR-1505 and SGR-3515 beyond Phase 1, indicating it may not advance them independently [sec_mda · as of 2026-05-05]
- Capital requirements are uncertain and depend on timing of milestone payments and potential distributions from equity stakes in collaborators [sec_mda · as of 2026-08-05]
- Relies on third-party cloud infrastructure and faces risks from tariffs and trade restrictions [sec · filed 2026-04-28]
From the filings
Quoted directly from source documents.
2025 total revenue growth
“Generated 2025 total revenue of $255.9 million, up 23.3 percent over 2024”
SEC filings · April 28, 2026
Phase 1 trial for SGR-1505
“Our ongoing Phase 1 clinical trial of SGR-1505 is designed as an open-label, multi-center dose escalation trial in patients with relapsed or refractory B-cell malignancies.”
SEC MD&A · May 5, 2026
Gates Foundation grant for predictive toxicology
“The project is being funded by $24.5 million in grants from the Gates Foundation.”
SEC MD&A · August 5, 2026
Risks & what to watch (4)›
Key risks
- Early-stage pipeline — Both clinical candidates (SGR-1505, SGR-3515) are in Phase 1; no later-stage data available [sec_mda · as of 2026-05-05]
- Dependence on partnerships — Company plans to seek partners for Phase 2+ development, creating reliance on external execution [sec_mda · as of 2026-05-05]
- Unpredictable capital needs — Capital requirements depend on milestone payments and equity distributions, which are inherently uncertain [sec_mda · as of 2026-08-05]
- External dependencies — Relies on third-party cloud infrastructure and is exposed to tariffs/trade restrictions [sec · filed 2026-04-28]
What to watch
- Phase 1 data readouts for SGR-1505 and SGR-3515 [sec · filed 2026-04-28]
- Commercial rollout of predictive toxicology solution and broader adoption in 2026 [sec_mda · as of 2026-08-05]
- Release of full commercial version of Bunsen by end of 2026 [sec_mda · as of 2026-08-05]
- Formation of strategic partnerships for SGR-1505 and SGR-3515 beyond Phase 1 [sec_mda · as of 2026-05-05]
Sources: Pipeline · SEC filings · SEC MD&A · Generated October 9, 2026 · How we verify sources →
Run Schrodinger, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Schrodinger, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.95 · 1% dilution
Lead: Phase 1
3 candidates
No upcoming catalysts tracked
0 buys · 4 sells (180d)
Pipeline
Financials
Short Interest
as of Apr 20, 2026- % of float
- 27.4%
- Days to cover
- 10.1
- Shares short
- 11,112,514
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SDGR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Schrodinger, Inc.?
Schrödinger, Inc. (SDGR) is a computational drug discovery company that develops a physics-based software platform and advances its own proprietary pipeline of preclinical and clinical drug programs.
What is Schrodinger, Inc.'s lead drug candidate?
Schrodinger, Inc.'s most advanced tracked candidate is sgr-1505 (Phase 1) for relapsed or refractory B-cell lymphomas.
Who is the CEO of Schrodinger, Inc.?
Dr. Ramy Farid Ph.D. is the chief executive officer of Schrodinger, Inc. (SDGR).
Where is Schrodinger, Inc. headquartered?
Schrodinger, Inc. (SDGR) is headquartered in New York, NY, United States.
What therapeutic areas does Schrodinger, Inc. focus on?
Schrodinger, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.